OS Therapies Secures $10M Credit Line and Appoints Dr. Eagle to Board
OSTX•OS Therapies named Chief Medical Advisor Dr. Craig Eagle to its board and secured a $10 million UK tax-credit–backed line of credit with an initial $1.6 million draw. The company agreed regulatory terms for its late-Q3 Phase 3 OST-HER2 trial, maintains cash runway into 2027 and targets a BLA filing by year-end 2026.
1. Board Appointment
Dr. Craig Eagle, OS Therapies’ Chief Medical Advisor, was elevated to the board of directors, providing strategic oversight as the company transitions from a development-stage to a commercial healthcare organization.
2. Line of Credit Financing
OS Therapies obtained a $10 million line of credit backed by its UK subsidiary’s tax credits, with an initial $1.6 million draw to support OST-HER2 manufacturing and future R&D investments without pledging its intellectual property.
3. Phase 3 Trial and Cash Runway
The company finalized regulatory alignment ahead of a late-Q3 start for its confirmatory Phase 3 OST-HER2 trial, expects sufficient cash to fund operations into 2027, and plans a Biologics License Application filing by year-end 2026.
